cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.15522834
title: LLMAID: Identifying AI Capabilities in Android Apps with LLM

description: Please refer to the README.md
DOI: 10.15468/dl.73swpb
title: Occurrence Download

description: A dataset containing 1331 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Meriones meridianus (Pallas, 1773)"
 ]
}

 The dataset includes 1331 records from 30 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002605-250525065834625/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.fsm6bw
title: Occurrence Download

description: A dataset containing 97297 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Medicago minima (L.) Bartal."
 ]
}

 The dataset includes 97297 records from 1341 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002584-250525065834625/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.31055548.v1
title: Supplementary Material for: Variability in Antibiotic Dosing and Resistance Development During Continuous Renal Replacement Therapy in Critically Ill Patients

description: Background: Antibiotic dosing in critically ill patients receiving continuous renal replacement therapy (CRRT) is challenging due to altered pharmacokinetics, variability in CRRT delivery, and limited dosing guidance. Optimizing therapy is essential, as underdosing may drive resistance and overdosing may increase toxicity, including cefepime-associated neurotoxicity.

Methods: We conducted a retrospective single-center study of ICU patients who received CRRT and at least one dose of cefepime, meropenem, or piperacillin-tazobactam between 2016 and 2020. Delivered CRRT dose was calculated from effluent rates. Daily antibiotic doses across CRRT phases were summarized, and resistance development was evaluated for Pseudomonas aeruginosa and Enterobacter cloacae using logistic regression.

Results: Of 954 eligible ICU patients, 661 met inclusion criteria. Median delivered CRRT dose was 29.5 mL/kg/h (IQR 25.0–33.5); 57.7% received ≥30 mL/kg/h, while only 9.6% were within the KDIGO-recommended 20–24.9 mL/kg/h. Median CRRT duration was 144 h (IQR 84–312), initiated a median of 2.3 days after ICU admission. Median daily doses during CRRT were 2.5 g for cefepime, 1.5 g for meropenem, and 10.8 g for piperacillin-tazobactam. Treatment-emergent resistance occurred in 17.6% of P. aeruginosa and 14.3% of E. cloacae isolates, while baseline resistance was common in E. coli (20.5%) and K. pneumoniae (27.3%). In multivariable models, longer treatment duration (OR 1.07/day, 95% CI 1.06–1.08), higher CRRT dose (OR 1.13 per 5 mL/kg/h, 95% CI 1.10–1.16), and lower daily antibiotic dose (OR 0.65 per g/day, 95% CI 0.61–0.70) were independently associated with cefepime resistance (AUC 0.73), with similar findings for meropenem (AUC 0.80).

Conclusion: Antibiotic dosing during CRRT was at the lower end of the therapeutic range and was associated with treatment-emergent resistance in exploratory analyses. These findings highlight the potential importance of CRRT-informed dosing strategies and underscore the need for careful balance between efficacy and toxicity.
DOI: 10.6084/m9.figshare.31055551
title: Supplementary Material for: Public Perspectives on Sharing Profits with Biospecimen Donors

description: Background: In current practice, individuals rarely share in the profits of research using their biospecimens. Many commentators defend this practice on the grounds that the contributions donors make are not important enough to merit a share of profits. Others argue that if researchers and sponsors profit, donors should too. Despite the importance of this debate, there are no data on the public’s views.

Subjects and Methods: On-line survey of US adults selected to approximate the 2020 US census on age, gender, race, ethnicity, and geographic region. Respondents were asked whether biospecimen donors should share in the profits or receive payments across six scenarios, differing on whether the research yields a profit and which other parties share in the profits.

Results: 77.2% of respondents indicated that donors should share in the profits when researchers profit and 78.9% when sponsors profit. Support for profit sharing was strong across all groups assessed, although respondents aged 65 and older were less likely to think donors should share in the profits.

Conclusions: A significant majority of a sample of the US public thinks individuals who donate their biospecimens should share in the profits of research that uses their samples. These findings offer compelling reason to reconsider current practice of not sharing profits with biospecimen donors.
DOI: 10.6084/m9.figshare.31055551.v1
title: Supplementary Material for: Public Perspectives on Sharing Profits with Biospecimen Donors

description: Background: In current practice, individuals rarely share in the profits of research using their biospecimens. Many commentators defend this practice on the grounds that the contributions donors make are not important enough to merit a share of profits. Others argue that if researchers and sponsors profit, donors should too. Despite the importance of this debate, there are no data on the public’s views.

Subjects and Methods: On-line survey of US adults selected to approximate the 2020 US census on age, gender, race, ethnicity, and geographic region. Respondents were asked whether biospecimen donors should share in the profits or receive payments across six scenarios, differing on whether the research yields a profit and which other parties share in the profits.

Results: 77.2% of respondents indicated that donors should share in the profits when researchers profit and 78.9% when sponsors profit. Support for profit sharing was strong across all groups assessed, although respondents aged 65 and older were less likely to think donors should share in the profits.

Conclusions: A significant majority of a sample of the US public thinks individuals who donate their biospecimens should share in the profits of research that uses their samples. These findings offer compelling reason to reconsider current practice of not sharing profits with biospecimen donors.
DOI: 10.15156/bio/sh1383338.10fu
title: SH1383338.10FU

description: UNITE provides a unified way for delimiting, identifying, communicating, and working with DNA-based Species Hypotheses (SH). All fungal ITS sequences in the international nucleotide sequence databases are clustered to approximately the species level by applying a set of dynamic distance values (<0.5 - 3.0%). All species hypotheses are given a unique, stable name in the form of a DOI, and their taxonomic and ecological annotations are verified through distributed, web-based third-party annotation efforts. SHs are connected to a taxon name and its classification as far as possible (phylum, class, order, etc.) by taking into account identifications for all sequences in the SH. An automatically or manually designated sequence is chosen to represent each such SH. These sequences are released (https://unite.ut.ee/repository.php) for use by the scientific community in, for example, local sequence similarity searches and next-generation sequencing analysis pipelines. The system and the data are updated automatically as the number of public fungal ITS sequences grows.
DOI: 10.6084/m9.figshare.31055557
title: Supplementary Material for: Sex differences in the risk of acute exacerbations among patients with chronic obstructive pulmonary disease treated with long-acting bronchodilators

description: Introduction: Several post-hoc analyses of clinical trials and observational studies have noticed that women may be at a higher risk of exacerbations than men among patients with chronic obstructive pulmonary disease (COPD), although the findings remain conflicting. These studies, however, did not consider the impact of mainstay treatments over longitudinal follow-up. We examined whether the risk of acute exacerbations differed between women and men in patients with COPD treated with long-acting bronchodilators. 

Methods: This population-based study included two cohorts of patients with COPD who initiated a single long-acting bronchodilator (mono-bronchodilator cohort) or a dual combination of long-acting bronchodilators (dual-bronchodilator cohort) identified from a nationwide Taiwanese claims database (2017-2022). In each cohort, Cox regression models were executed to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of moderate-to-severe exacerbations comparing women to men after 1:10 variable-ratio propensity score (PS) matching. 

Results: There were 51,945 patients (9,643 women, 42,302 men) in the mono-bronchodilator cohort and 88,271 patients (15,418 women, 72,853 men) in the dual-bronchodilator cohort after PS matching. The HR of moderate-to-severe exacerbations comparing women to men was 0.86 (95% CI, 0.80-0.92) and 0.88 (95% CI, 0.84-0.92) for each cohort, respectively. Results were consistent when analyzing moderate and severe exacerbations separately and did not change materially across pre-specified subgroup and sensitivity analyses. 

Conclusion: The present study including two sizable COPD cohorts of Asian patients suggests that women may have a lower risk of exacerbations than men when regularly receiving long-acting bronchodilators. The findings highlight the importance of considering maintenance treatments when evaluating sex differences in the risk of acute exacerbations.
DOI: 10.6084/m9.figshare.31055557.v1
title: Supplementary Material for: Sex differences in the risk of acute exacerbations among patients with chronic obstructive pulmonary disease treated with long-acting bronchodilators

description: Introduction: Several post-hoc analyses of clinical trials and observational studies have noticed that women may be at a higher risk of exacerbations than men among patients with chronic obstructive pulmonary disease (COPD), although the findings remain conflicting. These studies, however, did not consider the impact of mainstay treatments over longitudinal follow-up. We examined whether the risk of acute exacerbations differed between women and men in patients with COPD treated with long-acting bronchodilators. 

Methods: This population-based study included two cohorts of patients with COPD who initiated a single long-acting bronchodilator (mono-bronchodilator cohort) or a dual combination of long-acting bronchodilators (dual-bronchodilator cohort) identified from a nationwide Taiwanese claims database (2017-2022). In each cohort, Cox regression models were executed to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of moderate-to-severe exacerbations comparing women to men after 1:10 variable-ratio propensity score (PS) matching. 

Results: There were 51,945 patients (9,643 women, 42,302 men) in the mono-bronchodilator cohort and 88,271 patients (15,418 women, 72,853 men) in the dual-bronchodilator cohort after PS matching. The HR of moderate-to-severe exacerbations comparing women to men was 0.86 (95% CI, 0.80-0.92) and 0.88 (95% CI, 0.84-0.92) for each cohort, respectively. Results were consistent when analyzing moderate and severe exacerbations separately and did not change materially across pre-specified subgroup and sensitivity analyses. 

Conclusion: The present study including two sizable COPD cohorts of Asian patients suggests that women may have a lower risk of exacerbations than men when regularly receiving long-acting bronchodilators. The findings highlight the importance of considering maintenance treatments when evaluating sex differences in the risk of acute exacerbations.
DOI: 10.6084/m9.figshare.31055560
title: Supplementary Material for: Systematic Review of Methylenetetrahydrofolate reductase (MTHFR) 677C&gt;T and 1298A&gt;C Variants and Treatment-Resistant Depression: Insights for Precision Psychiatry

description: Introduction: Treatment-resistant depression (TRD) is a major clinical challenge, affecting approximately one-third of patients with major depressive disorder (MDD). Genetic factors, particularly genetic variants in the MTHFR gene, have been implicated in antidepressant response variability. The MTHFR 677C&gt;T (rs1801133) and 1298A&gt;C (rs1801131) variants are associated with altered folate metabolism, increased homocysteine levels, and potential disruptions in neurotransmitter synthesis, which may contribute to TRD. This systematic review aims to evaluate the association between MTHFR variants and TRD, exploring their potential role in predicting antidepressant response and guiding personalized treatment strategies.
Methods: A systematic literature search was conducted following PRISMA guidelines (PROSPERO registration: CRD42024612628). Studies were included if they investigated MTHFR 677C&gt;T and/or 1298 A&gt;C variants in adults with MDD and assessed their association with TRD.
Results: Seven studies met the inclusion criteria, and the findings indicate a potential link between MTHFR 677TT and 1298CC genotypes and an increased risk of TRD. However, conflicting evidence exists, as other studies found no significant effect of the MTHFR variants on treatment outcomes. Variability in study designs, definitions of TRD, and confounding factors such as dietary folate intake and comorbidities contribute to inconsistencies in findings.
Conclusion: While evidence suggests a role for MTHFR variants in TRD, heterogeneity among studies limits definitive conclusions. Future research should standardize TRD definitions, control for confounding factors, and explore the integration of genetic testing into clinical practice. L-methyl folate supplementation may represent a promising adjunctive strategy for MDD patients carrying MTHFR risk variants.
DOI: 10.6084/m9.figshare.31055560.v1
title: Supplementary Material for: Systematic Review of Methylenetetrahydrofolate reductase (MTHFR) 677C&gt;T and 1298A&gt;C Variants and Treatment-Resistant Depression: Insights for Precision Psychiatry

description: Introduction: Treatment-resistant depression (TRD) is a major clinical challenge, affecting approximately one-third of patients with major depressive disorder (MDD). Genetic factors, particularly genetic variants in the MTHFR gene, have been implicated in antidepressant response variability. The MTHFR 677C&gt;T (rs1801133) and 1298A&gt;C (rs1801131) variants are associated with altered folate metabolism, increased homocysteine levels, and potential disruptions in neurotransmitter synthesis, which may contribute to TRD. This systematic review aims to evaluate the association between MTHFR variants and TRD, exploring their potential role in predicting antidepressant response and guiding personalized treatment strategies.
Methods: A systematic literature search was conducted following PRISMA guidelines (PROSPERO registration: CRD42024612628). Studies were included if they investigated MTHFR 677C&gt;T and/or 1298 A&gt;C variants in adults with MDD and assessed their association with TRD.
Results: Seven studies met the inclusion criteria, and the findings indicate a potential link between MTHFR 677TT and 1298CC genotypes and an increased risk of TRD. However, conflicting evidence exists, as other studies found no significant effect of the MTHFR variants on treatment outcomes. Variability in study designs, definitions of TRD, and confounding factors such as dietary folate intake and comorbidities contribute to inconsistencies in findings.
Conclusion: While evidence suggests a role for MTHFR variants in TRD, heterogeneity among studies limits definitive conclusions. Future research should standardize TRD definitions, control for confounding factors, and explore the integration of genetic testing into clinical practice. L-methyl folate supplementation may represent a promising adjunctive strategy for MDD patients carrying MTHFR risk variants.
DOI: 10.6084/m9.figshare.31055563
title: Supplementary Material for: The role of temperature in shaping the nervous system phenotype in the epaulette shark (Hemiscyllium ocellatum)

description: Introduction
Over the last century, sea surface temperatures have increased by more than 0.5˚C, with predictions suggesting an increase of 1-4˚C by 2100. Oceanic warming poses significant challenges to marine species, particularly those with physiological and developmental processes that are tightly linked to environmental conditions. In cartilaginous fishes, including sharks, the brain grows continually throughout life, supported by the capacity for lifelong neurogenesis. This feature suggests that the nervous system – both peripheral (sensory) and central (brain) – of sharks may be highly plastic and able to adapt dynamically to a changing environment. 
Methods
We investigated the effects of elevated rearing temperature on brain development in the epaulette shark (Hemiscyllium ocellatum), a species known for its tolerance of environmental fluctuations in intertidal habitats. Eggs (n = 12) were sourced from a breeding stock at the New England Aquarium and reared in either ambient (27°C) or elevated (31°C, 4°C above ambient) seawater temperatures until two months post-hatch. Using histological analyses, we compared the relative volume of the nose (olfactory rosette), total brain, and major brain regions between treatment groups.
Results
Despite this species’ natural exposure to temperature variability, Generalized Linear Models revealed that elevated temperature significantly altered the volume of the olfactory sensory epithelium, olfactory bulbs, and medulla oblongata after accounting for overall brain size. Analyses of proportional brain region volumes also showed that elevated temperature was associated with reduced olfactory bulb size and increased subpallial volume relative to total brain size. These changes may suggest potential changes in cognitive capacity related to olfactory processing as well as sensory and / or motor functions at elevated temperatures. 
Conclusions
While short-term studies, such as this one, cannot capture long-term adaptive potential, understanding the impacts of elevated temperature on brain phenotypes provides critical insights into how elasmobranchs may cope with changing ocean conditions. Such knowledge will be vital for predicting the resilience of these ecologically important species to future environmental stressors.
DOI: 10.6084/m9.figshare.31055563.v1
title: Supplementary Material for: The role of temperature in shaping the nervous system phenotype in the epaulette shark (Hemiscyllium ocellatum)

description: Introduction
Over the last century, sea surface temperatures have increased by more than 0.5˚C, with predictions suggesting an increase of 1-4˚C by 2100. Oceanic warming poses significant challenges to marine species, particularly those with physiological and developmental processes that are tightly linked to environmental conditions. In cartilaginous fishes, including sharks, the brain grows continually throughout life, supported by the capacity for lifelong neurogenesis. This feature suggests that the nervous system – both peripheral (sensory) and central (brain) – of sharks may be highly plastic and able to adapt dynamically to a changing environment. 
Methods
We investigated the effects of elevated rearing temperature on brain development in the epaulette shark (Hemiscyllium ocellatum), a species known for its tolerance of environmental fluctuations in intertidal habitats. Eggs (n = 12) were sourced from a breeding stock at the New England Aquarium and reared in either ambient (27°C) or elevated (31°C, 4°C above ambient) seawater temperatures until two months post-hatch. Using histological analyses, we compared the relative volume of the nose (olfactory rosette), total brain, and major brain regions between treatment groups.
Results
Despite this species’ natural exposure to temperature variability, Generalized Linear Models revealed that elevated temperature significantly altered the volume of the olfactory sensory epithelium, olfactory bulbs, and medulla oblongata after accounting for overall brain size. Analyses of proportional brain region volumes also showed that elevated temperature was associated with reduced olfactory bulb size and increased subpallial volume relative to total brain size. These changes may suggest potential changes in cognitive capacity related to olfactory processing as well as sensory and / or motor functions at elevated temperatures. 
Conclusions
While short-term studies, such as this one, cannot capture long-term adaptive potential, understanding the impacts of elevated temperature on brain phenotypes provides critical insights into how elasmobranchs may cope with changing ocean conditions. Such knowledge will be vital for predicting the resilience of these ecologically important species to future environmental stressors.
DOI: 10.6084/m9.figshare.31055566
title: Supplementary Material for: The Global Macroeconomic Burden of Spinal Cord Injury: A Dynamic Modelling Study from 2020 to 2050

description: Background
Spinal cord injury (SCI) is a debilitating condition that imposes profound and persistent socioeconomic burdens. Despite its relatively low prevalence, SCI results in lifelong disability, reduced productivity, and sustained healthcare costs, particularly among working-age populations. While clinical aspects of SCI have been extensively studied, its broader macroeconomic burden remains underexplored.
Methods
We developed a dynamic macroeconomic model to estimate the long-term economic burden of SCI across 191 countries and territories from 2020 to 2050. The model integrated epidemiological data from the Global Burden of Disease (GBD) 2019 study with macroeconomic indicators to assess the impact of SCI on labor supply and physical capital accumulation. A counterfactual scenario, assuming the absence of SCI-related disability and healthcare costs, was used to estimate the economic burden. Sensitivity analyses were performed using Monte Carlo simulations and varying social discount rates.
Findings
Globally, the cumulative macroeconomic burden of SCI between 2020 and 2050 is estimated at INT$5.58 trillion. The highest absolute burdens were observed in China, the USA, and India, while the highest relative burdens as a share of GDP occurred in Iraq (0.26%), Burundi (0.20%), and Sri Lanka (0.17%). High-income countries (HICs) bore the greatest total cost (INT$2.84 trillion), driven by intensive care utilization and prolonged survival. However, low-income countries experienced the highest burden relative to income per capita, highlighting fiscal vulnerability. The burden of SCI was primarily driven by reduced labor force participation and long-term healthcare expenditures, significantly constraining national savings and investment.
Interpretation
SCI imposes a substantial and uneven macroeconomic burden, with profound implications for national productivity and fiscal resilience. Economic consequences are shaped not only by disease prevalence but also by institutional capacity and health system responsiveness. Investments in SCI prevention, rehabilitation, and social protection are urgently needed, particularly in LMICs, to mitigate long-term economic burden. Our findings offer empirical evidence to inform global health financing and disability policy.